MOH inks term sheet agreements with two vaccine suppliers 26 Jan 2021 / 21:35 H.
KUALA LUMPUR: The Ministry of Health (MOH) today signed term sheet agreements with two vaccine suppliers, Pharmaniaga Lifescience Sdn Bhd (PLS) and Duopharma (M) Sdn Bhd for the procurement of 18.4 million doses of Covid-19 vaccine for 28.75 per cent of the Malaysian population.
MOH, in a statement today said PLS would supply 12 million doses of Covid-19 CORONAVAC, SARS-COV-2 Vaccine (Vero Cell) Inactivated produced by Sinovac Life Science Co. Ltd, which would be distributed in stages beginning April.
“Duopharma will supply 6.4 million doses of Sputnik V vaccine, produced by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. The vaccine is expected to be distributed in stages by end-March 2021,” it said.
Health Ministry inks agreements with vaccine suppliers
January 26, 2021
KUALA LUMPUR – The Ministry of Health (MOH) today signed term sheet agreements with two vaccine suppliers, Pharmaniaga Lifescience Sdn Bhd (PLS) and Duopharma (M) Sdn Bhd for the procurement of 18.4 million doses of COVID-19 vaccine for 28.75 per cent of the Malaysian population.
MOH, in a statement today said PLS would supply 12 million doses of COVID-19 CORONAVAC, SARS-COV-2 Vaccine (Vero Cell) Inactivated produced by Sinovac Life Science Co. Ltd, which would be distributed in stages beginning April.
Advertisement
“Duopharma will supply 6.4 million doses of Sputnik V vaccine, produced by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. The vaccine is expected to be distributed in stages by end-March 2021,” it said.
BW Businessworld
Sinovac COVID-19 Vaccine Unit Struggles To Add New Hires As Holiday Nears
Sinovac has outsourced some procedures of filling vials and syringes and finishing packing the vaccine to partners in Indonesia and Brazil, allowing it to export bulk materials to lower production costs.
Photo Credit :
A Beijing unit of Sinovac Biotech manufacturing a COVID-19 vaccine said it is facing difficulties in finding staff to expand production because of surging local infections and the imminent Lunar New Year holiday.
Eleven people living in the Daxing district of the capital, Beijing, where Sinovac Life Science is based, were confirmed as COVID-19 patients between Sunday and Wednesday, forcing authorities to seal up some residential compounds and launch a mass testing scheme.
A Beijing unit of Sinovac Biotech manufacturing a COVID-19 vaccine said it is facing difficulties in finding staff to expand production because of surging local infections and the imminent Lunar New Year holiday.
BEIJING (Reuters) - A unit of Sinovac Biotech could double annual production capacity of its CoronaVac COVID-19 vaccine to 1 billion doses by February, the group s chairman said on Wednesday. More than 7 million doses of CoronaVac vaccine, one of the three China has included in its emergency vaccination programme, have so far been supplied to regions including the city of Beijing and Guangdong province, Sinovac Biotech Chairman Yin Weidong told a news conference. While the first phase of Sinovac Life Sciences existing production line can make 500 million CoronaVac doses in one year, another with annual capacity of 500 million doses could become operational by February, Yin said. Researchers in Brazil on Tuesday released new efficacy data for the vaccine, for which there have been varying rates of success from trial sites in three countries. Trials in different countries are designed differently, but the CoronaVac doses being tested came from the same batch, Yin said. These Phase III c